<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162941">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01654796</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001233</org_study_id>
    <nct_id>NCT01654796</nct_id>
  </id_info>
  <brief_title>Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression</brief_title>
  <acronym>RAPID</acronym>
  <official_title>Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at the safety and efficacy of low frequency magnetic stimulation
      (LFMS) for treating patients with treatment resistant depression who are taking an
      antidepressant that is not working for them.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression - 6 items</measure>
    <time_frame>past 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This instrument is completed with a structured interview guide  by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week.The time frame for this scale is the past 24 hours.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Low Frequency Magnetic Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive 4 days of active low frequency magnetic stimulation (LFMS) treatment, a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham (LFMS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 days of sham (not active) low frequency magnetic stimulation (LFMS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this group will receive two days of sham low frequency magnetic stimulation (LFMS) followed by two days of active LFMS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Frequency Magnetic Stimulation (LFMS)</intervention_name>
    <description>The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.</description>
    <arm_group_label>Low Frequency Magnetic Stimulation</arm_group_label>
    <arm_group_label>Crossover Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham LFMS</intervention_name>
    <description>SHam LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.</description>
    <arm_group_label>Sham (LFMS)</arm_group_label>
    <arm_group_label>Crossover Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-65 years old

          -  Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major
             Depressive Episode (MDE) of at least eight weeks

          -  A participant has TRD of the current MDE

          -  Good general health

          -  For female participants, status of non-childbearing potential or use of an acceptable
             form of birth control

          -  Body mass index between 18-40 kg/m2

          -  Concurrent psychotherapy will be allowed if the type and frequency of the therapy has
             been stable for at least three months prior to screening is expected to remain stable
             during participation in the study

          -  Concurrent hypnotic therapy will be allowed if the therapy has been stable for at
             least 4 weeks prior to screening and is expected to remain stable during the
             subject's participation in the study

        Exclusion Criteria:

          -  A woman of childbearing potential who is not willing to use one of the specified
             forms of birth control during the study

          -  Pregnant or breastfeeding

          -  A woman with a positive pregnancy test at screening or baseline

          -  Participant has TRD of the current MDE with failure to achieve a satisfactory
             response) as perceived by the subject to &gt;3 treatment courses of a therapeutic dose
             of an antidepressant therapy at least six weeks duration

          -  Participant has a current diagnosis of a Substance Use Disorder with the exception of
             nicotine dependence, at screening or within six months prior to screening

          -  Current diagnosis of Axis I disorders other than Generalized Anxiety Disorder, Social
             Anxiety Disorder, Panic Disorder, Specific Phobia, Post Traumatic Stress Disorder or
             Complicated Grief (unless one of these is comorbid and clinically unstable, and/or
             the focus of the participant's treatment for the past six months or more).

          -  Subject has a history of schizophrenia or schizoaffective disorders, any history of
             psychotic symptoms or is on antipsychotic medication for the treatment of psychotic
             symptoms

          -  Subject has a history of eating disorders within five years of screening

          -  Subject has any Axis I or Axis II Disorder, which at screening is clinically
             predominant to their MDD or has been predominant at any time within six months prior
             to screening

          -  The participant is considered at significant risk for suicide during the study

          -  Subject has had electroconvulsive therapy in the current episode of depression

          -  Subject has had Transcranial Magnetic Stimulation or has received treatment with
             other experimental devices for the treatment in the current episode of depression

          -  Subject has received Vagus Nerve Stimulation at any time

          -  Dementia, delirium, amnestic, or other cognitive disorders

          -  There is a clinically significant abnormality on the screening physical examination

          -  Participation in any clinical trial with an investigational drug or device within the
             past month or concurrent to study participation

          -  Known history or current episode of:

             --Uncontrolled hypertension, Recent myocardial infarction (within one year) or a
             history of more than one myocardial infarction, Syncopal event within the past year,
             Congestive heart failure, Angina pectoris

          -  Chronic lung disease

          -  Lifetime history of surgical procedures involving the brain or meninges encephalitis,
             meningitis, degenerative central nervous system disorder, epilepsy, mental
             retardation, any other disease/procedure/accident/intervention associated with
             significant injury to or malfunction of the central nervous system, history of
             significant head trauma within the past two years, or is currently receiving
             anticonvulsant therapy

          -  Lab abnormalities are present

          -  History of hypothyroidism and has been on a stable dosage of thyroid replacement
             medication, or was surgically treated less than six months prior to screening

          -  Any current or past history of any physical condition which in the investigator's
             opinion might put the subject at risk or interfere with the interpretation of study
             results

          -  History of positive screening urine test for drugs of abuse

          -  Patient with any non-removable stimulation device

          -  Patients requiring treatment with excluded concomitant medications

          -  Patients who cannot be in a MRI

          -  Patients who are unable to lie on their back for 20 minutes or more

          -  Patients who are currently using a metal intrauterine device (IUD)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Iosifescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medecine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Sanacora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madhukar Trivedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital (Coordinating Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Rapaport, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Shelton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univsity of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George I Papakostas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medecine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Overall Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
